Author

Ravishankara Nagaraja

Observed name: RAVISHANKARA NAGARAJA

OpenAlex ID: A5113296366

766-P: Safety and Tolerability of Once-Weekly GL0034 (Utreglutide) in Healthy Individuals—A Multiple Ascending Dose Study

2023 · RAJAMANNAR THENNATI, VINOD S. BURADE, et al. · Diabetes · 2

Abstract 4345579: Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist Reduces Liver Fat Content along with Blood Pressure in Post-menopausal Females with Obesity: A Phase 1a/2b Study

2025 · Rajamannar Thennati, Vinod Burade, et al. · Circulation · 1

759-P: Effects of Once-Weekly Utreglutide (GL0034) in Individuals with Overweight and Obesity on Lipid Metabolism—A 10-Week Exploratory Proof-of-Concept Study

2025 · RAJAMANNAR THENNATI, VINOD S. BURADE, et al. · Diabetes · 1

765-P: A Single Ascending Dose Study of the Novel GLP-1 Receptor Agonist GL0034 (Utreglutide) in Obese Individuals without Diabetes

2023 · RAJAMANNAR THENNATI, VINOD S. BURADE, et al. · Diabetes · 1

2833-LB: Utreglutide (GL0034) Shows Comparable Tolerability and Efficacy with Different Dose Escalation Regimens in Overweight and Obese Adults with Type 2 Diabetes (T2DM)

2026 · RAJAMANNAR THENNATI, GRIT ANDERSEN, et al. · Diabetes

1700-P: Durable Cardiometabolic Effects of Utreglutide in Metabolic Dysfunction–Associated Steatotic Liver Disease Patients with Nondiabetic and Prediabetic Status

2026 · RAJAMANNAR THENNATI, VINOD BURADE, et al. · Diabetes

FRI-199 Effect of utreglutide on cardio-metabolic and non-invasive fibrotic biomarkers in participants with metabolic-dysfunction associated steatotic liver disease

2026 · Rajamannar Thennati, Vinod Burade, et al. · Journal of Hepatology

SAT-448 A 10-week, randomized, double blind, placebo-controlled exploratory proof of concept study of Utreglutide (GL0034) in individuals with overweight and obesity

2025 · Rajamannar Thennati, Vinod Burade, et al. · Journal of Hepatology

Abstract 4116298: Once Weekly Utreglutide (GL0034), a Glucagon-like Peptide-1 Receptor Agonist, at 4 × 450 µg Doses Reduces Blood Pressure, Lipids, and Body Weight in Post-menopausal Females: A Phase I Study

2024 · Rajamannar Thennati, Vinod Burade, et al. · Circulation

121-OR: Safety, Tolerability, and Metabolic Effects of Once-Weekly GL0034 (Utreglutide) in Individuals with Obesity—A Multiple Ascending Dose Study

2024 · RAJAMANNAR THENNATI, VINOD S. BURADE, et al. · Diabetes

SAT-231 GL0034 (Utreglutide), a long acting, glucagon-like peptide-1 receptor agonist, improves body weight loss, lipid and liver injury markers in individuals with obesity: A phase 1 multiple ascending dose study

2024 · Rajamannar Thennati, Vinod Burade, et al. · Journal of Hepatology

GL0034 (Utreglutide), a novel, long acting, glucagon-like peptide 1 receptor agonist (GLP-1 RA), results of a phase 1 study in healthy individuals

2023 · Rajamannar Thennati, Vinod Burade, et al. · Journal of Hepatology

Works count: 12

Citation count: 5

H-index: 1

I10-index: